TSE:RVX - Resverlogix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$3.41 -0.05 (-1.45 %) (As of 05/19/2019 04:00 PM ET)Previous CloseC$3.41Today's RangeC$3.40 - C$3.5352-Week RangeC$1.11 - C$4.94Volume94,100 shsAverage Volume80,804 shsMarket CapitalizationC$683.12 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada. Receive RVX News and Ratings via Email Sign-up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:RVX Previous Symbol CUSIPN/A CIKN/A Webwww.resverlogix.com Phone+1-403-2549252Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow103.33 Book ValueC($0.80) per share Price / Book-4.26Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares200,328,992Market CapC$683.12 million Next Earnings Date7/29/2019 (Estimated) OptionableNot Optionable Resverlogix (TSE:RVX) Frequently Asked Questions What is Resverlogix's stock symbol? Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX." How were Resverlogix's earnings last quarter? Resverlogix Corp. (TSE:RVX) announced its earnings results on Friday, March, 15th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.05. View Resverlogix's Earnings History. When is Resverlogix's next earnings date? Resverlogix is scheduled to release their next quarterly earnings announcement on Monday, July 29th 2019. View Earnings Estimates for Resverlogix. What is the consensus analysts' recommendation for Resverlogix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Resverlogix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Resverlogix. Has Resverlogix been receiving favorable news coverage? Media coverage about RVX stock has trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Resverlogix earned a news impact score of 1.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are some of Resverlogix's key competitors? Some companies that are related to Resverlogix include Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), ProMetic Life Sciences (PLI), Polynovo (PNV), Mesoblast (MSB), Emerald Health Therapeutics (EMH), Biotest (BIO), Starpharma (SPL), Oxford BioMedica (OXB), Theratechnologies (TH), Neptune Wellness Solutions (NEPT), Senesco Technologies (ELOX), Kodiak Sciences (KOD) and OncoCyte (OCX). What other stocks do shareholders of Resverlogix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Oncolytics Biotech (ONC), Endocyte (ECYT), ZIX (ZIXI), Repros Therapeutics (RPRX) and Allena Pharmaceuticals (ALNA). Who are Resverlogix's key executives? Resverlogix's management team includes the folowing people: Mr. Donald J. McCaffrey, Co-Founder, Pres, CEO & ChairmanMr. Aaron Bradley Cann CA, CPA, CBV, Chief Financial OfficerMr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.Dr. Jan O. Johansson, Sr. VP of Medical AffairsDr. Michael Sweeney, Sr. VP of Clinical Devel. (Age 58) How do I buy shares of Resverlogix? Shares of RVX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Resverlogix's stock price today? One share of RVX stock can currently be purchased for approximately C$3.41. How big of a company is Resverlogix? Resverlogix has a market capitalization of C$683.12 million. What is Resverlogix's official website? The official website for Resverlogix is http://www.resverlogix.com/. How can I contact Resverlogix? Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252. MarketBeat Community Rating for Resverlogix (TSE RVX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 128 (Vote Outperform)Underperform Votes: 75 (Vote Underperform)Total Votes: 203MarketBeat's community ratings are surveys of what our community members think about Resverlogix and other stocks. Vote "Outperform" if you believe RVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Why Net Income is Important to Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.